
Zoom On: William Fay, Director - Division of Cardiovascular Medicine



William Fay, Professor

*****@***missouri.edu

Director, Division of Cardiovascular
Medicine - University of Missouri

Dr. William Fay is the Director, Division of Cardiovascular Medicine, Professor of medicine and medical pharmacology and physiology and the J.W. & Lois Winifred Stafford Distinguished Chair in Diabetes and Cardiovascular Research at the University of Missouri School of Medicine. Dr. Fay graduated from the University of Illinois College of Medicine and specialises in Cardiovascular Disease and Internal Medicine.

With over thirty years of experience in this field, Dr. Fay's primary research interests include an investigation of the role of leukocyte-derived tissue factor in thrombosis, the role of plasminogen activator inhibitor-1 (PAI-1) in the proliferative response to vascular injury, mechanisms by which C-reactive protein (CRP) modulates thrombosis, role of heme oxygenase-1 in thrombosis and regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor (TAFI).

The primary techniques Dr. Fay has focused on include mouse gene targeting, rodent models of human vascular disease, structure-function studies of coagulation proteins and thrombosis models. Dr. Fay and his team mainly focuses on the roles of blood coagulation and fibrinolytic systems in vascular disease. Their goal is to determine acute thrombus formation after vascular injury and the molecular processes that regulate subsequent thrombolysis thereafter.

The projects Dr. Fay's involved in address the role of plasminogen activator inhibitor-1 as a risk factor for myocardial infarction, and the molecular basis of the variable sensitivity of patients to anticoagulation with warfarin.

The University of Missouri Health Care's University Hospital has received the American College of Cardiology's ACTION Registry - Get the Guidelines (GWTG) Silver Performance Achievement Award for 2015. This award recognises hospitals that have sustained performance measure score composite of 90 percent or better in the treatment of heart attack over a 12-month period.

According to Dr. Fay, this achievement reflects the hard work and dedication of our staff and physicians who care for some of our most seriously ill patients.

Source: University of Missouri

Image Credit: University of Missouri

Published on : Tue, 21 Jul 2015